Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity

The study explores the role of the colour Doppler scanning of the renal arteries and its relation to the degree of disease affection in lupus nephritis

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Systemic Lupus Erthematosus Autoimmune Diseases Connective Tissue Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Immune System Diseases Kidney Diseases Lupus Erythematosus, Systemic Lupus Flare Lupus Glomerulonephritis Lupus Nephritis Male Urogenital Diseases Nephritis Skin and Connective Tissue Diseases Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cairo University Hospitals

Cairo, Egypt

About this study

we have recruited patients into 3 groups The first group is patients with lupus nephritis The second groups is patients with systemic lupus erythromatosus without nephritis The third groups is normal healthy controls we explored the association of colour Doppler and the renal resistive index with the degree of the renal affection in lupus nephritis

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1. Systemic lupus erythematosus. 2. Lupus nephritis. 3. Adults >18 years old.

Exclusion criteria

1. End Stage Renal Disease. 2. Diabetes Mellitus. 3. Heart failure. 4. Hepatic diseases. 5. Obstructive nephropathy. 6. Renal artery stenosis or occlusion.

Treatment and study plan

colour doppler of the renal artery and measurement of resistive index

Diagnostic Test

using colour doppler to asses vascular resistance and resistive index

Primary outcomes

Resistive index

Time frame: At the time of recruitment

The resistive index of the renal arteries as measured by the colour Doppler

Sponsors and collaborators

Lead sponsor

Kasr El Aini Hospital

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Jan 3, 2025
Registry last updated: Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed